Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).

Authors

Mark Pomerantz

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Mark Pomerantz , Xin Victoria Wang , Philip W. Kantoff , Wanling Xie , Manish Kohli , Gwo-Shu Mary Lee , Elaine Wang , Yu-Hui Chen , Noah M. Hahn , David Frazier Jarrard , Glenn Liu , Jorge A. Garcia , Michael Anthony Carducci , Robert S. DiPaola , Matthew L Freedman , Christopher Sweeney

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Cancer Prevention, Genetics, and Epidemiology

Track

Prevention, Risk Reduction, and Genetics

Sub Track

Cancer Genetics

Citation

J Clin Oncol 34, 2016 (suppl; abstr 1540)

DOI

10.1200/JCO.2016.34.15_suppl.1540

Abstract #

1540

Poster Bd #

363

Abstract Disclosures

FEATURED

Genome-wide association study (GWAS) of response to androgen deprivation therapy (ADT) and survival in metastatic prostate cancer (PCa).

Authors

Mark Pomerantz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Poster Details

Meeting

Session Type

Session Title

Track

Sub Track

Citation

DOI

Abstract #

Poster Bd #

Similar Posters

Poster

Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Poster

Genome-wide association study (GWAS) of cisplatin-related hearing loss in testicular cancer survivors (TCS) to reveal associated variant in Wolfram syndrome 1 (WFS1) gene.

Poster

A genome-wide association study (GWAS) of overall survival (OS) in 609 metastatic colorectal cancer (mCRC) patients treated with chemotherapy and biologics in CALGB 80405.

Poster

Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).